Through exclusive interviews with the Malaysian Minister of Health as well as the head of the country’s regulatory body – the NPRA – this report examines emerging trends in Malaysian healthcare, with Prime Minister Tun Dr. Mahathir Mohamad spearheading a bold health policy reform.
Also explored is the emergence of the halal medicine niche – where Malaysia has the potential to be a global leader given its geographic links to Southeast Asia and cultural ties to the Middle East – the first Malaysian biosimilars, the country’s outstanding potential as a regional clinical research hub and the rise of medical tourism.
KUALA LUMPUR, 28 November 2018 – Clinical Research Malaysia (CRM) today signed a memorandum of understanding (MoU) to establish a strategic alliance with IQVIA’s global Early Phase Oncology Network (EPON).
The agreement makes Clinical Research Centre at Sarawak General Hospital the first in Southeast Asia to be part of IQVIA’s prestigious network of globally qualified Phase I oncology sites. CRM, established by the Malaysian Ministry of Health in 2012, exists to advance Malaysia’s ability to contribute to global health solutions. IQVIA is a leading global provider of contract research services, advanced analytics and technology solutions to the life-sciences industry.
“This agreement is a major step forward for the country of Malaysia to provide advanced Phase I studies for investigational cancer therapies,” said CRM Chief Executive Officer Dr Akhmal Yusof. “Advances in genomics offer new hope for targeted oncology products. Through this agreement, Sarawak General Hospital will join IQVIA’s global Early Phase Oncology Network, which is designed to provide fast, high-quality Phase I oncology studies to biopharmaceutical companies.”
IQVIA Asia Pacific President Anand Tharmaratnam said: “This agreement builds upon our long relationship with Clinical Research Malaysia as an IQVIA Prime Site. Adding Sarawak General Hospital’s research centre gives biopharma companies, for the first time, a Southeast Asia location as part of IQVIA’s global network of high quality early phase oncology research sites. This is a significant step forward in our joint mission to accelerate the development of targeted oncology therapies in Malaysia and Asia for the benefit of patients worldwide.”
IQVIA has been conducting oncology early clinical research in Asia Pacific for more than two decades. The IQVIA EPON-Clinical Research Malaysia strategic alliance is designed to streamline study startup, enhance consistency, and deliver high-quality results faster.
This collaboration is intended significantly improve the quality of early phase oncology trials in Malaysia by having innovative investigational therapies as an option for patients. This aligns with the Phase I Realization Project (P1RP) that was launched by CRM in 2016 which is focused in enhancing Malaysia’s early phase clinical research capacity and building a more attractive early phase clinical research ecosystem.
The MoU is signed between Dr Akhmal Yusof and on behalf of IQVIA, Mr. Teck Kwang Koh, General Manager at IQVIA Malaysia. The signing of the MoU was witnessed by the Director of Network of Clinical Research Centre, YBhg. Dato’ Dr. Goh Pik Pin, Dr Voon Pei Jye of Sarawak General Hospital, Mr. Desmond Dorairajoo, Head of Academic Research Group Asia-Pacific IQVIA and Mr. David Horsburgh, Asia Strategy Lead, Academic Research Group Asia-Pacific IQVIA.
Established by the Malaysian Ministry of Health in 2012, CRM exists to advance global health solutions for a brighter, more hopeful future for the people by providing speedy and reliable end-to-end clinical research support for quality studies. CRM’s innate understanding of the local clinical research landscape with the international standards of operations coupled with fundamental backing of the government ministries provide us an incomparable advantage to work with partners from the nascent stages of development to materialisation of the end product, in order to deliver better treatment and high skilled job opportunities.
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With more than 55,000 employees, IQVIA conducts operations in more than 100 countries.To learn more, visit www.iqvia.com.
TOKYO, 6 November 2018 – Clinical Research Malaysia (CRM) hold a half-day seminar that targets Japanese pharmaceutical and medical device companies interested in conducting clinical trials in the Asian region. This is the first time for CRM to deliver a clinical trial seminar focusing on its home country in Japan.
Dr Akhmal Yusof, CEO of CRM sheds light on the capacity for all stages of clinical research in Malaysia. He discusses the importance of human resources for the country’s research future and explains what makes Malaysia such a worthwhile location to invest in international clinical research.
Hospital Sultanah Bahiyah (HSB) officially operated at its new building complex on 29 July 2007 after a complete transfer and replacing Hospital Alor Setar. Located 6 km from the centre of Alor Setar City, and within the sight of the PLUS North-South Highway, its location makes Hospital Sultanah Bahiyah easily accessible to the public. Surrounded by a vast area of paddy fields, this building complex incorporates 4 main buildings, namely the Medical Support Block, Ward Block, Main Block and Non-Medical Support Block. Read more
Before I joined Sibu Hospital, I have worked in the United Kingdom, Singapore and Australia for a number of years as a paediatric trainee. Besides general paediatrics, I also work in the areas of developmental-behavioural paediatrics and community child health. I am an Adjunct Professor for SEGi University Medical School as well as the Special Olympics Asia Pacific Regional Clinical Advisor in Health Promotion®, Vice President for the National Early Childhood Intervention Council, Council Member for Sarawak State Council for Early Childhood Education and Development, National Assessor for the Baby-Friendly Hospital Initiative and Secretary of the Association for Children with Special Needs Sibu. Besides scientific papers, I have also published parent-teacher handbooks on ADHD, language development and breastfeeding, as well as children reading / colouring books, and books on Chinese literary prose/short stories. I received The Outstanding Young Malaysian Award in 2010, and Special Education Network in Asia Advocacy Award in 2018.
KUALA LUMPUR, 24 September 2018 – The 12thNational Conference for Clinical Research (NCCR) brought together medical experts and researchers under one platform to understand the way digital technology can impact the Malaysian healthcare delivery system, thus potentially improving patient outcomes.
PETALING JAYA, 7 September 2018 – Clinical Research Malaysia (CRM) had the signing of CRM Education Scholarship Agreement between CRM and National Pharmaceutical Regulatory Agency – NPRA officer, Ms. Lee Wei Xin, signing witness on behalf of NPRA was Mr. Tan Ann Ling (Director of Enforcement Division) for the Phase I Realization Project (P1RP) earlier today.
CLINICAL RESEARCH MALAYSIA
D-26-06, Menara Suezcap 1
KL Gateway, No. 2 Jalan Kerinchi
Gerbang Kerinchi Lestari
59200 Kuala Lumpur
Tel: +603 7931 5566
Fax: +603 7931 9940
In The News
- Mainstreaming May Improve Access to Ovarian Cancer Genetic Testing in Malaysia
- Hepatitis C Elimination Through Access to Diagnostics (Head-Start) Comes to Malaysia!
- Hospital Raja Perempuan Zainab II
- Journey to success in Phase 1b Clinical Study for Hepatitis B at the University Malaya Medical Centre, Malaysia
- Research Personality: Dato’ Dr Mahiran Mustafa
Disclaimer | Personal Data Protection Act Notice